The moment of truth awaits Novo's diabetes pill: "It's really, really important"

Friday is the deadline for FDA's review of Novo Nordisk's diabetes tablet, oral semaglutide. Analysts anticipate an approval and blockbuster sales figures in future. Physician and patient association consider the drug "important for certain patients."

Lars Fruergaard Jørgensen, adm. direktør i Novo Nordisk, får senest fredag svar på, om selskabets fremtidige væksthåb oral semaglutid bliver godkendt til salg i USA. Photo: Søren Bidstrup / Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles